Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH)
Abstract Background Hematopoietic cell transplantation (HCT) is a curative option for a growing number of patients with hematologic diseases and malignancies. However, HCT-related factors, such as total body irradiation used for conditioning, graft-versus-host disease, and prolonged exposure to immu...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
BMC
2020-08-01
|
| 丛编: | BMC Cancer |
| 主题: | |
| 在线阅读: | http://link.springer.com/article/10.1186/s12885-020-07232-2 |
| _version_ | 1831532518687375360 |
|---|---|
| author | Saro H. Armenian Lanie Lindenfeld Aleksi Iukuridze Meagan Echevarria Samantha Bebel Catherine Coleman Ryotaro Nakamura Farah Abdullah Badri Modi Kevin C. Oeffinger Karen M. Emmons Ashfaq A. Marghoob Alan C. Geller |
| author_facet | Saro H. Armenian Lanie Lindenfeld Aleksi Iukuridze Meagan Echevarria Samantha Bebel Catherine Coleman Ryotaro Nakamura Farah Abdullah Badri Modi Kevin C. Oeffinger Karen M. Emmons Ashfaq A. Marghoob Alan C. Geller |
| author_sort | Saro H. Armenian |
| collection | DOAJ |
| description | Abstract Background Hematopoietic cell transplantation (HCT) is a curative option for a growing number of patients with hematologic diseases and malignancies. However, HCT-related factors, such as total body irradiation used for conditioning, graft-versus-host disease, and prolonged exposure to immunosuppressive therapy, result in very high risk for melanoma and non-melanoma skin cancer (NMSC). In fact, skin cancer is the most common subsequent neoplasm in HCT survivors, tending to develop at a time when survivors’ follow-up care has largely transitioned to the primary care setting. The goal of this study is to increase skin cancer screening rates among HCT survivors through patient-directed activation alone or in combination with physician-directed activation. The proposed intervention will identify facilitators of and barriers to risk-based screening in this population and help reduce the burden of cancer-related morbidity after HCT. Methods/design 720 HCT survivors will be enrolled in this 12-month randomized controlled trial. This study uses a comparative effectiveness design comparing (1) patient activation and education (PAE, N = 360) including text messaging and print materials to encourage and motivate skin examinations; (2) PAE plus primary care physician activation (PAE + Phys, N = 360) adding print materials for the physician on the HCT survivors’ increased risk of skin cancer and importance of conducting a full-body skin exam. Patients on the PAE + Phys arm will be further randomized 1:1 to the teledermoscopy (PAE + Phys+TD) adding physician receipt of a portable dermatoscope to upload images of suspect lesions for review by the study dermatologist and an online course with descriptions of dermoscopic images for skin cancers. Discussion When completed, this study will provide much-needed information regarding strategies to improve skin cancer detection in other high-risk (e.g. radiation-exposed) cancer survivor populations, and to facilitate screening and management of other late effects (e.g. cardiovascular, endocrine) in HCT survivors. Trial registration ClinicalTrials.gov, NCT04358276 . Registered 24 April 2020. |
| first_indexed | 2024-12-16T21:47:10Z |
| format | Article |
| id | doaj.art-a6d38a0af59f4e80a9cc7a4edb5101d4 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-16T21:47:10Z |
| publishDate | 2020-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-a6d38a0af59f4e80a9cc7a4edb5101d42022-12-21T22:15:04ZengBMCBMC Cancer1471-24072020-08-0120111110.1186/s12885-020-07232-2Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH)Saro H. Armenian0Lanie Lindenfeld1Aleksi Iukuridze2Meagan Echevarria3Samantha Bebel4Catherine Coleman5Ryotaro Nakamura6Farah Abdullah7Badri Modi8Kevin C. Oeffinger9Karen M. Emmons10Ashfaq A. Marghoob11Alan C. Geller12Department of Population Sciences, City of HopeDepartment of Population Sciences, City of HopeDepartment of Population Sciences, City of HopeDepartment of Population Sciences, City of HopeDepartment of Population Sciences, City of HopeDepartment of Population Sciences, Dana-Farber Cancer InstituteDepartment of Hematology & Hematopoietic Cell Transplantation, City of HopeDepartment of Surgery, City of HopeDepartment of Surgery, City of HopeDepartment of Medicine, Community and Family Medicine and Population Health Sciences, Duke Cancer InstitutionDepartment of Social and Behavioral Sciences, Harvard TH Chan School of Public HealthDepartment of Dermatology, Memorial-Sloan Kettering Cancer CenterDepartment of Social and Behavioral Sciences, Harvard TH Chan School of Public HealthAbstract Background Hematopoietic cell transplantation (HCT) is a curative option for a growing number of patients with hematologic diseases and malignancies. However, HCT-related factors, such as total body irradiation used for conditioning, graft-versus-host disease, and prolonged exposure to immunosuppressive therapy, result in very high risk for melanoma and non-melanoma skin cancer (NMSC). In fact, skin cancer is the most common subsequent neoplasm in HCT survivors, tending to develop at a time when survivors’ follow-up care has largely transitioned to the primary care setting. The goal of this study is to increase skin cancer screening rates among HCT survivors through patient-directed activation alone or in combination with physician-directed activation. The proposed intervention will identify facilitators of and barriers to risk-based screening in this population and help reduce the burden of cancer-related morbidity after HCT. Methods/design 720 HCT survivors will be enrolled in this 12-month randomized controlled trial. This study uses a comparative effectiveness design comparing (1) patient activation and education (PAE, N = 360) including text messaging and print materials to encourage and motivate skin examinations; (2) PAE plus primary care physician activation (PAE + Phys, N = 360) adding print materials for the physician on the HCT survivors’ increased risk of skin cancer and importance of conducting a full-body skin exam. Patients on the PAE + Phys arm will be further randomized 1:1 to the teledermoscopy (PAE + Phys+TD) adding physician receipt of a portable dermatoscope to upload images of suspect lesions for review by the study dermatologist and an online course with descriptions of dermoscopic images for skin cancers. Discussion When completed, this study will provide much-needed information regarding strategies to improve skin cancer detection in other high-risk (e.g. radiation-exposed) cancer survivor populations, and to facilitate screening and management of other late effects (e.g. cardiovascular, endocrine) in HCT survivors. Trial registration ClinicalTrials.gov, NCT04358276 . Registered 24 April 2020.http://link.springer.com/article/10.1186/s12885-020-07232-2Hematopoietic cell transplantationSurvivorsSkin cancerSkin self-examinationDermoscopyEarly detection |
| spellingShingle | Saro H. Armenian Lanie Lindenfeld Aleksi Iukuridze Meagan Echevarria Samantha Bebel Catherine Coleman Ryotaro Nakamura Farah Abdullah Badri Modi Kevin C. Oeffinger Karen M. Emmons Ashfaq A. Marghoob Alan C. Geller Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH) BMC Cancer Hematopoietic cell transplantation Survivors Skin cancer Skin self-examination Dermoscopy Early detection |
| title | Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH) |
| title_full | Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH) |
| title_fullStr | Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH) |
| title_full_unstemmed | Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH) |
| title_short | Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH) |
| title_sort | technology enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers teach |
| topic | Hematopoietic cell transplantation Survivors Skin cancer Skin self-examination Dermoscopy Early detection |
| url | http://link.springer.com/article/10.1186/s12885-020-07232-2 |
| work_keys_str_mv | AT saroharmenian technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT lanielindenfeld technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT aleksiiukuridze technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT meaganechevarria technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT samanthabebel technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT catherinecoleman technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT ryotaronakamura technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT farahabdullah technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT badrimodi technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT kevincoeffinger technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT karenmemmons technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT ashfaqamarghoob technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach AT alancgeller technologyenabledactivationofskincancerscreeningforhematopoieticcelltransplantationsurvivorsandtheirprimarycareprovidersteach |